News
ENGN
1.620
-1.22%
-0.020
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
PR Newswire · 3d ago
enGene Holdings Shareholders Approve Board and Auditor Slate
TipRanks · 4d ago
enGene Therapeutics held annual shareholder meeting
PUBT · 4d ago
EnGene Therapeutics: The Selloff Creates An Opportunity
Seeking Alpha · 6d ago
Weekly Report: what happened at ENGN last week (0601-0605)?
Weekly Report · 6d ago
Weekly Report: what happened at ENGN last week (0525-0529)?
Weekly Report · 06/01 09:11
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
Barchart · 05/29 07:49
Weekly Report: what happened at ENGN last week (0518-0522)?
Weekly Report · 05/25 09:11
Weekly Report: what happened at ENGN last week (0511-0515)?
Weekly Report · 05/18 09:11
enGene Holdings Is Maintained at Neutral by UBS
Dow Jones · 05/14 21:41
enGene Holdings Price Target Cut to $2.00/Share From $9.00 by UBS
Dow Jones · 05/14 21:41
enGene price target lowered to $2 from $9 at UBS
TipRanks · 05/14 15:24
ENGENE THERAPEUTICS INC <ENGN.O>: UBS CUTS TARGET PRICE TO $2 FROM $9
Reuters · 05/14 12:14
Weekly Report: what happened at ENGN last week (0504-0508)?
Weekly Report · 05/11 09:11
enGene Therapeutics announces annual shareholder meeting webcast
PUBT · 05/08 20:08
Leerink downgraded enGene to Market Perform following LEGEND update
TipRanks · 05/08 18:32
enGene downgraded to Perform from Outperform at Oppenheimer
TipRanks · 05/08 16:22
Why Is enGene Therapeutics Stock Falling Friday?
Benzinga · 05/08 15:34
enGene Holdings Cut to Market Perform From Market Outperform by Citizens
Dow Jones · 05/08 14:56
Citizens Downgrades enGene Therapeutics to Market Perform
Benzinga · 05/08 14:46
More
Webull provides a variety of real-time ENGN stock news. You can receive the latest news about enGene Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENGN
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).